Page last updated: 2024-11-01

nortriptyline and Parkinson Disease

nortriptyline has been researched along with Parkinson Disease in 14 studies

Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research Excerpts

ExcerptRelevanceReference
" In a 14-week randomized trial comparing pramipexole with sertraline in depressed patients without motor complications, the Hamilton Depression Rating Scale score decreased in both groups; however, in the pramipexole group, the proportion of patients who recovered was significantly higher."4.87Treatment of depressive symptoms in Parkinson's disease. ( Barone, P, 2011)
"Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo."2.75The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease. ( Bienfait, KL; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M; Tröster, A, 2010)
"Nortriptyline was superior to placebo for the change in HAM-D (p < 0."2.74A controlled trial of antidepressants in patients with Parkinson disease and depression. ( Bienfait, K; Buyske, S; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M, 2009)
"It suggests that successfully treating depression in PD leads to important, sustained improvements in these outcomes and that patients who improve on antidepressants are less likely to relapse than are patients who initially improve on placebo."2.74The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. ( Bienfait, K; Buyske, S; Dicke, A; Dobkin, RD; Gara, M; Marin, H; Mark, MH; Menza, M, 2009)
"The authors suggest the depression in Parkinson's disease to be of both reactive and endogenous origins."2.65Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. ( Aabro, E; Andersen, J; Gulmann, N; Hjelmsted, A; Pedersen, HE, 1980)
"Although anxiety is associated with Parkinson's disease, anxiety disorders can begin before the onset of motor symptoms, and have been linked to a possible abnormality of dopaminergic, serotonergic, and adrenergic neurons that precedes motor disturbance."2.58Pharmacological interventions for anxiety in Parkinson's disease sufferers. ( Kohsaka, M; Oeda, T; Park, K; Sawada, H; Tomita, S; Umemura, A; Yamamoto, K, 2018)
"Dementia is a disorder that is characterized by a chronic, progressive loss of cognitive function."1.39Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia. ( Lee, EK; Lee, YJ, 2013)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19904 (28.57)18.7374
1990's1 (7.14)18.2507
2000's3 (21.43)29.6817
2010's5 (35.71)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Schrag, A2
Carroll, C2
Duncan, G2
Molloy, S2
Grover, L2
Hunter, R2
Brown, R2
Freemantle, N2
Whipps, J2
Serfaty, MA2
Lewis, G2
Sawada, H1
Umemura, A1
Kohsaka, M1
Tomita, S1
Park, K1
Oeda, T1
Yamamoto, K1
Lee, EK1
Lee, YJ1
Menza, M4
Dobkin, RD4
Marin, H4
Mark, MH4
Gara, M4
Buyske, S2
Bienfait, K2
Dicke, A4
Bienfait, KL2
Tröster, A1
Friedman, J1
Barone, P1
Andersen, J1
Aabro, E1
Gulmann, N1
Hjelmsted, A1
Pedersen, HE1
Hinds, NP1
Hillier, CE1
Wiles, CM1
Gabriel, E1
Karobath, M1
Lenz, G1
Driver, PS1
Harvey, NS1
Patni, SK1
Dandiya, PC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Depression in Patients With Parkinson's Disease[NCT00062738]Phase 252 participants (Actual)Interventional2003-06-30Completed
Study of Antidepressants in Parkinson's Disease[NCT00086190]Phase 3115 participants (Actual)Interventional2005-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hamilton Depression Scale

total score on HDRS (0-54 higher score is worse) (NCT00062738)
Timeframe: 8 weeks

Interventionunits on a scale (Least Squares Mean)
Nortriptyline10.84
Paroxetine12.45
Placebo15.81

Percent Responders

Percent of patients who had a 50% decrease in total HDRS at 8 weeks (NCT00062738)
Timeframe: 8 weeks

Interventionpercent of patients who were responders (Number)
Nortriptyline53
Paroxetine11
Placebo24

Change in Beck Depression Inventory II (BDI-II)

Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in BDI-II score (Mean)
Paroxetine-9.7
Venlafaxine Extended Release-9.6
Placebo-5.2

Change in Brief Psychiatric Rating Scale (BPRS)

Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in BPRS score (Mean)
Paroxetine-9.0
Venlafaxine Extended Release-9.8
Placebo-4.4

Change in Geriatric Depression Rating Scale (GDS)

Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in GDS score (Mean)
Paroxetine-6.9
Venlafaxine Extended Release-6.9
Placebo-2.8

Change in Hamilton Depression Rating Scale (HAM-D) Scores

Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in HAM-D score (Mean)
Paroxetine-13.0
Venlafaxine Extended Release-11.0
Placebo-6.8

Change in Montgomery-Asberg Depression Rating Scale (MADRS)

Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in MADRS score (Mean)
Paroxetine-13.6
Venlafaxine Extended Release-10.9
Placebo-6.6

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being

Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in PDQ-39 Emotional score (Mean)
Paroxetine-21.4
Venlafaxine Extended Release-20.7
Placebo-10.9

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall

Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in PDQ-39 score (Mean)
Paroxetine-8.0
Venlafaxine Extended Release-8.4
Placebo-5.3

Change in Pittsburgh Sleep Quality Index (PSQI)

Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in PQSI score (Mean)
Paroxetine-2.1
Venlafaxine Extended Release-2.6
Placebo-1.1

Change in Short Form 36 Health Survey - Mental Component Summary

Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 mental score (Mean)
Paroxetine11.4
Venlafaxine Extended Release9.5
Placebo4.8

Change in Short Form 36 Health Survey - Mental Health

Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 Mental Health score (Mean)
Paroxetine16.7
Venlafaxine Extended Release17.4
Placebo9.7

Change in Short Form 36 Health Survey - Role-Emotional

Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 Role score (Mean)
Paroxetine39.5
Venlafaxine Extended Release26.9
Placebo12.7

Change in Short Form 36 Health Survey - Vitality

Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 vitality score (Mean)
Paroxetine13.5
Venlafaxine Extended Release9.1
Placebo4.7

Change in Snaith Clinical Anxiety Scale (CAS)

Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in CAS score (Mean)
Paroxetine-3.6
Venlafaxine Extended Release-3.2
Placebo-2.4

Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS score (Mean)
Paroxetine-8.7
Venlafaxine Extended Release-7.0
Placebo-4.3

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar

Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS-Bulbar score (Mean)
Paroxetine-1.4
Venlafaxine Extended Release-1.4
Placebo-0.5

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor

Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS-motor score (Mean)
Paroxetine-4.3
Venlafaxine Extended Release-2.0
Placebo-1.0

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor

Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS-tremor score (Mean)
Paroxetine0.4
Venlafaxine Extended Release0.5
Placebo-0.6

Reviews

3 reviews available for nortriptyline and Parkinson Disease

ArticleYear
Pharmacological interventions for anxiety in Parkinson's disease sufferers.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:10

    Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Dopamine; Dopamine Agonists; Humans; Nortriptyl

2018
Treatment of depressive symptoms in Parkinson's disease.
    European journal of neurology, 2011, Volume: 18 Suppl 1

    Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dop

2011
Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
    Psychosomatics, 1986, Volume: 27, Issue:2

    Topics: Antidepressive Agents; Clozapine; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Female;

1986

Trials

7 trials available for nortriptyline and Parkinson Disease

ArticleYear
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
    BMC neurology, 2022, Dec-12, Volume: 22, Issue:1

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic

2022
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
    BMC neurology, 2022, Dec-12, Volume: 22, Issue:1

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic

2022
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
    BMC neurology, 2022, Dec-12, Volume: 22, Issue:1

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic

2022
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
    BMC neurology, 2022, Dec-12, Volume: 22, Issue:1

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic

2022
A controlled trial of antidepressants in patients with Parkinson disease and depression.
    Neurology, 2009, Mar-10, Volume: 72, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co

2009
A controlled trial of antidepressants in patients with Parkinson disease and depression.
    Neurology, 2009, Mar-10, Volume: 72, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co

2009
A controlled trial of antidepressants in patients with Parkinson disease and depression.
    Neurology, 2009, Mar-10, Volume: 72, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co

2009
A controlled trial of antidepressants in patients with Parkinson disease and depression.
    Neurology, 2009, Mar-10, Volume: 72, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Co

2009
The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Jul-15, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depression; Disability Evaluation; Double-Bli

2009
The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.
    The Journal of neuropsychiatry and clinical neurosciences, 2010,Spring, Volume: 22, Issue:2

    Topics: Adult; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepre

2010
Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2011, Volume: 19, Issue:3

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Dysthymic Disorder; Female;

2011
Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA.
    Acta neurologica Scandinavica, 1980, Volume: 62, Issue:4

    Topics: Aged; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Combination; Female;

1980
Depression treatment in Parkinson's disease.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:2

    Topics: Antidepressive Agents, Tricyclic; Carbidopa; Depression; Double-Blind Method; Drug Interactions; Dru

1991

Other Studies

4 other studies available for nortriptyline and Parkinson Disease

ArticleYear
Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia.
    International journal of clinical pharmacy, 2013, Volume: 35, Issue:5

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cholinergic Antagonists; Comorbidity; Dementia; Elect

2013
Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism.
    Journal of neurology, 2000, Volume: 247, Issue:10

    Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Depressive Disorder; Drug Interactions; Fema

2000
[The extrapyramidal symptoms in the combination of lithium long-term lithium therapy with nortriptyline. A case report on the formation of a pathogenesis hypothesis].
    Der Nervenarzt, 1976, Volume: 47, Issue:1

    Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Chlorprothixene; Clopenthixol; Dibenzazepines; Drug

1976
The influence of monoamine oxidase inhibitors and some other antidepressants on the anti-parkinsonian activity of sub-effective doses of diphenylhydramine in rats and mice.
    Japanese journal of pharmacology, 1972, Volume: 22, Issue:3

    Topics: Animals; Antidepressive Agents; Catatonia; Diphenhydramine; Humans; Mice; Monoamine Oxidase Inhibito

1972